US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
المصدر: The Guardian World | Source: The Guardian WorldExperts say any short-term financial benefit will be outweighed by long-term health costs related to obesity
Faced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.
The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years.
Continue reading...
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة The Guardian World. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by The Guardian World. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
